| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0002027 | Regulation of heart rate | Affects phenotype | PMID:35305976 |
| GO:0004602 | Glutathione peroxidase activity | Decreases phenotype | PMID:24001619 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:24001619 |
| GO:0006497 | Protein lipidation | Affects phenotype | PMID:35149085 |
| GO:0006631 | Fatty acid metabolic process | Affects phenotype | PMID:35305976 |
| GO:0006641 | Triglyceride metabolic process | Affects phenotype | PMID:33383043; PMID:39536891; PMID:35305976; PMID:39536891 |
| GO:0006644 | Phospholipid metabolic process | Affects phenotype | PMID:35305976 |
| GO:0006750 | Glutathione biosynthetic process | Decreases phenotype | PMID:24001619 |
| GO:0006954 | Inflammatory response | Increases phenotype | PMID:39536891 |
| GO:0008203 | Cholesterol metabolic process | Affects phenotype | PMID:33383043; PMID:39536891; PMID:35305976; PMID:39536891 |
| GO:0008206 | Bile acid metabolic process | Affects phenotype | PMID:33383043 |
| GO:0008219 | Cell death | Increases phenotype | PMID:35149085 |
| GO:0010659 | Cardiac muscle cell apoptotic process | Increases phenotype | PMID:28106847 |
| GO:0010884 | Positive regulation of lipid storage | Increases phenotype | PMID:26408789 |
| GO:0020027 | Hemoglobin metabolic process | Affects phenotype | PMID:35305976 |
| GO:0042755 | Eating behavior | Affects phenotype | PMID:35305976 |
| GO:0042756 | Drinking behavior | Affects phenotype | PMID:35305976 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:31709706; PMID:33359023; PMID:34806916; PMID:35149085; PMID:39536891 |
| GO:0045444 | Fat cell differentiation | Increases phenotype | PMID:24001619 |
| GO:0045600 | Positive regulation of fat cell differentiation | Increases phenotype | PMID:26408789 |
| GO:0045795 | Positive regulation of cell volume | Increases phenotype | PMID:39536891 |
| GO:0045822 | Negative regulation of heart contraction | Increases phenotype | PMID:39059093 |
| GO:0046209 | Nitric oxide metabolic process | Affects phenotype | PMID:35305976 |
| GO:0055074 | Calcium ion homeostasis | Affects phenotype | PMID:31709706 |
| GO:0060038 | Cardiac muscle cell proliferation | Decreases phenotype | PMID:28106847 |
| GO:0062000 | Positive regulation of cardiac endothelial to mesenchymal transition | Increases phenotype | PMID:39059093 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:39536891 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:28106847 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:26408789 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.